GMep Medical Technology GmbH

AmbroSpray®-Innovative-The only Ambroxol in the form of oral spray
AmbroSpray® is indicated for the mucolytic treatment of acute and chronic bronchopulmonary diseases characterized by impaired mucous formation and transportation.
Produced in Italy
Current Registered in 10 European Countries
Including: Germany, Italy, Poland, Portugal, Bulgaria, Czech, Slovakia, Ukraine, Hungary
ü Accurate dose, convenient and fast administration
ü Reasonable 5% concentration, safe and effective
ü Easy to swallow, avoid choking risk
ü No need to wash the cup
ü No need for medical staff to assist in drug administration, greatly liberate the nursing staff
ü Bedridden patients do not need to get up to take the drug

Dosage: 13mL （50mg/mL）

Usage： 3 spray puffs each time (10mg/puff, 0.2ml), three times per day for adults and children over 6 years. This equals 30 mg ambroxol hydrochloride three times per day